JP2012532194A5 - - Google Patents

Download PDF

Info

Publication number
JP2012532194A5
JP2012532194A5 JP2012519612A JP2012519612A JP2012532194A5 JP 2012532194 A5 JP2012532194 A5 JP 2012532194A5 JP 2012519612 A JP2012519612 A JP 2012519612A JP 2012519612 A JP2012519612 A JP 2012519612A JP 2012532194 A5 JP2012532194 A5 JP 2012532194A5
Authority
JP
Japan
Prior art keywords
acid
formulation
layer
pharmaceutically acceptable
tpr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012519612A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012532194A (ja
Filing date
Publication date
Priority claimed from US12/688,493 external-priority patent/US20110003005A1/en
Application filed filed Critical
Publication of JP2012532194A publication Critical patent/JP2012532194A/ja
Publication of JP2012532194A5 publication Critical patent/JP2012532194A5/ja
Pending legal-status Critical Current

Links

JP2012519612A 2009-07-06 2010-07-02 持続放出オンダンセトロン組成物を用いたpdnv及びponvの処置方法 Pending JP2012532194A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US22321809P 2009-07-06 2009-07-06
US61/223,218 2009-07-06
US12/688,493 US20110003005A1 (en) 2009-07-06 2010-01-15 Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
US12/688,493 2010-01-15
PCT/US2010/040868 WO2011005671A1 (en) 2009-07-06 2010-07-02 Methods of treating pdnv and ponv with extended release ondansetron compositions

Publications (2)

Publication Number Publication Date
JP2012532194A JP2012532194A (ja) 2012-12-13
JP2012532194A5 true JP2012532194A5 (enExample) 2013-08-22

Family

ID=43412803

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012519612A Pending JP2012532194A (ja) 2009-07-06 2010-07-02 持続放出オンダンセトロン組成物を用いたpdnv及びponvの処置方法

Country Status (8)

Country Link
US (1) US20110003005A1 (enExample)
EP (1) EP2451276A4 (enExample)
JP (1) JP2012532194A (enExample)
AR (1) AR077394A1 (enExample)
BR (1) BR112012000095A2 (enExample)
TW (1) TW201105657A (enExample)
UY (1) UY32767A (enExample)
WO (1) WO2011005671A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2506714A4 (en) * 2009-11-30 2013-07-03 Aptalis Pharmatech Inc MOUTH ONDANSETRON TABLET COMPOSITIONS TO PREVENT EVIL AND CRUSH
DK2605655T3 (en) 2010-08-19 2019-02-04 Buck Institute For Age Res METHODS OF TREATING SMALL COGNITIVE DISABILITY (MCI) AND RELATED DISORDERS
WO2013123426A1 (en) * 2012-02-18 2013-08-22 Buck Institute For Research On Aging Formulations and methods for the treatment or prophylaxis of pre-mci and/or pre-alzheimer's conditions
US10071088B2 (en) * 2012-06-26 2018-09-11 Precondit, Llc Anti-nausea drug combinations
US9636305B2 (en) * 2013-03-14 2017-05-02 Redhill Biopharma Ltd. Antiemetic extended release solid dosage forms
CA2919892C (en) 2013-08-12 2019-06-18 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
JP6461186B2 (ja) 2014-03-11 2019-01-30 レッド ヒル バイオファーマ リミテッドRedHill Biopharma Ltd. 悪心、嘔吐または下痢の症状を処置するためのオンダンセトロン徐放固形製剤
DK3169315T3 (da) 2014-07-17 2020-08-10 Pharmaceutical Manufacturing Res Services In Væskefyldt doseringsform til forhindring af misbrug med øjeblikkelig frigivelse
EP3209282A4 (en) 2014-10-20 2018-05-23 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
GB201618425D0 (en) * 2016-11-01 2016-12-14 Acacia Pharma Ltd method
GB201702250D0 (en) 2017-02-10 2017-03-29 Acacia Pharma Ltd Method

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3634584A (en) * 1969-02-13 1972-01-11 American Home Prod Sustained action dosage form
GB1468172A (en) * 1973-03-28 1977-03-23 Benzon As Alfred Oral drug preparations
US3954959A (en) * 1973-03-28 1976-05-04 A/S Alfred Benzon Oral drug preparations
DE2336218C3 (de) * 1973-07-17 1985-11-14 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Orale Arzneiform
DD146547A5 (de) * 1978-07-15 1981-02-18 Boehringer Sohn Ingelheim Arzneimittel-retardform mit unloeslichen poroesen diffusionshuellen
CH647676A5 (fr) * 1978-12-22 1985-02-15 Donald E Panoz Formes galeniques a usage oral, a liberation programmee et leurs procedes de preparation.
DE3000979A1 (de) * 1980-01-12 1981-07-23 Dr. Karl Thomae Gmbh, 7950 Biberach Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
DE3124090A1 (de) * 1981-06-19 1983-01-05 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale dipyridamolformen
DE3126703A1 (de) * 1981-07-07 1983-01-27 Dr. Karl Thomae Gmbh, 7950 Biberach Bromhexin-retardform und verfahren zu ihrer herstellung
DE3237575A1 (de) * 1982-10-09 1984-04-12 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale mopidamolformen
IE55745B1 (en) * 1983-04-06 1991-01-02 Elan Corp Plc Sustained absorption pharmaceutical composition
IE56459B1 (en) * 1983-12-21 1991-08-14 Elan Corp Ltd Controlled absorption pharmaceutical formulation
IE56999B1 (en) * 1983-12-22 1992-03-11 Elan Corp Plc Pharmaceutical formulation
US4894240A (en) * 1983-12-22 1990-01-16 Elan Corporation Plc Controlled absorption diltiazem formulation for once-daily administration
EP0225085A1 (en) * 1985-11-13 1987-06-10 ELAN CORPORATION, Plc Controlled absorption pharmaceutical formulation
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
IE58401B1 (en) * 1986-06-20 1993-09-08 Elan Corp Plc Controlled absorption pharmaceutical composition
DE3627423A1 (de) * 1986-08-13 1988-02-18 Thomae Gmbh Dr K Arzneimittel enthaltend dipyridamol oder mopidamol und o-acetylsalicylsaeure bzw. deren physiologisch vertraegliche salze, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung der thrombusbildung
AU2016992A (en) * 1991-05-20 1992-12-30 Marion Laboratories, Inc. Multi-layered controlled release formulation
US5464632C1 (en) * 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
US5837284A (en) * 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US5705190A (en) * 1995-12-19 1998-01-06 Abbott Laboratories Controlled release formulation for poorly soluble basic drugs
US5840329A (en) * 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
DE69901938T3 (de) * 1998-03-06 2012-08-02 Aptalis Pharma S.R.L. Schnell zerfallende tablette
US6602521B1 (en) * 1998-09-29 2003-08-05 Impax Pharmaceuticals, Inc. Multiplex drug delivery system suitable for oral administration
HU230454B1 (hu) * 1998-11-02 2016-07-28 Alkermes Pharma Ireland Limited Metilfenidátot tartalmazó módosított felszabadulású sokszemcsés készítmény
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6936275B2 (en) * 1999-12-20 2005-08-30 Scolr, Inc. Amino acid modulated extended release dosage form
JP2004508278A (ja) * 2000-01-20 2004-03-18 デルシス ファーマシューティカル コーポレイション 多段薬物投与形態
US6627223B2 (en) * 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
US6500457B1 (en) * 2000-08-14 2002-12-31 Peirce Management, Llc Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
WO2003000169A1 (fr) * 2001-06-20 2003-01-03 Takeda Chemical Industries, Ltd. Procede de fabrication de comprimes
DE10149674A1 (de) * 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
US20040019096A1 (en) * 2001-10-23 2004-01-29 Vlassios Andronis Novel formulations of carvedilol
US6663888B2 (en) * 2001-12-14 2003-12-16 Eurand Pharmaceuticals Ltd. Pulsatile release histamine H2 antagonist dosage form
MY143789A (en) * 2003-02-18 2011-07-15 Helsinn Healthcare Sa Use of palonosetron treating post- operative nausea and vomiting
US20040265375A1 (en) * 2003-04-16 2004-12-30 Platteeuw Johannes J. Orally disintegrating tablets
US8545881B2 (en) * 2004-04-19 2013-10-01 Eurand Pharmaceuticals, Ltd. Orally disintegrating tablets and methods of manufacture
US9050249B2 (en) * 2004-04-30 2015-06-09 Astellas Pharma Inc. Oral pharmaceutical compositions in timed-release particle form and fast-disintegrating tablets containing this composition
US20060280795A1 (en) * 2005-06-08 2006-12-14 Dexcel Pharma Technologies, Ltd. Specific time-delayed burst profile delivery system
CA2635313C (en) * 2005-12-29 2013-12-31 Osmotica Corp. Triple combination release multi-layered tablet
KR20140088230A (ko) * 2006-01-27 2014-07-09 앱탈리스 파마테크, 인코포레이티드 약 염기성 약물과 유기산을 포함하는 약물 전달 시스템
AU2007211091B8 (en) * 2006-01-27 2013-08-29 Adare Pharmaceuticals, Inc. Drug delivery systems comprising weakly basic selective serotonin 5-HT3 blocking agent and organic acids
NZ576237A (en) * 2006-10-24 2011-12-22 Helsinn Healthcare Sa Soft capsules comprising palonosetron hydrochloride having improved stability and bioavailability
US8133506B2 (en) * 2008-03-12 2012-03-13 Aptalis Pharmatech, Inc. Drug delivery systems comprising weakly basic drugs and organic acids

Similar Documents

Publication Publication Date Title
JP2012532194A5 (enExample)
KR101752014B1 (ko) 고용량 및 저용량 약물들의 조합을 포함하는 구강붕해정 조성물
JP2013199488A5 (enExample)
TWI440480B (zh) 包含弱鹼性藥物及有機酸之藥物遞送系統
JP2013512250A5 (enExample)
JP5878022B2 (ja) 抗コリン薬を具える放出制御組成物
JP2012532194A (ja) 持続放出オンダンセトロン組成物を用いたpdnv及びponvの処置方法
KR102408645B1 (ko) 안정성이 증가된 에스오메프라졸 함유 이중코팅정 조성물 및 이의 제조방법
MX2007010889A (es) Formulaciones farmaceuticas gastrorresistentes que contienen rifaximina.
JP2012518655A5 (enExample)
JP2013518870A5 (enExample)
JP2011509295A5 (enExample)
CN105392486A (zh) 口腔崩解片
CA2584419A1 (en) New modified release tablet formulations for proton pump inhibitors
US20110135724A1 (en) Ondansetron Orally Disintegrating Tablet Compositions for Prevention of Nausea and Vomiting
CN101428005A (zh) 泮托拉唑及其钠盐肠溶缓释微丸制剂
WO2021018414A1 (en) Pharmaceutical composition comprising dabigatran etexilate
CN100393304C (zh) 一种包含酸不稳定药物的微细颗粒及其制剂
AU2007311493B2 (en) Multiple unit tablet compositions of benzimidazole compounds
JP2019507181A5 (enExample)
CN100431526C (zh) 一种酸敏感型药物的快速崩解片剂
CN107249569A (zh) 一种包含含有盐酸坦索罗辛的缓释颗粒的口服药物制剂
JP2013536832A (ja) ミルナシプランの制御放出医薬組成物
JP5919173B2 (ja) 徐放性塩酸アンブロキソール口腔内崩壊錠
WO2017145146A1 (en) Compositions comprising proton pump inhibitors